Skip to content
Study details
Enrolling now

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Obsidian Therapeutics, Inc.
NCT IDNCT06060613ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

52

Study length

about 4.7 years

Ages

18+

Locations

9 sites in CA, FL, KY +4

What this study is about

This trial is testing the safety and effectiveness of a new treatment called OBX-115 for people with advanced solid tumors. The goal is to see if OBX-115 can help shrink or control cancer growth, while also monitoring how well it's tolerated.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive OBX-115

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1

Secondary: Incidence of AEs, The proportion of participants who have a confirmed CR or PR per RECIST v1.1

Body systems

Oncology